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Abstract
Background: Antibiotic consumption in hospitals is commonly measured using the accumulated amount of drugs
delivered from the pharmacy to ward held stocks. The reliability of this method, particularly the impact of the
length of the registration periods, has not been evaluated and such evaluation was aim of the study.
Methods: During 26 weeks, we performed a weekly ward stock count of use of broad-spectrum antibiotics - that
is second- and third-generation cephalosporins, carbapenems, and quinolones - in five hospital wards and
compared the data with corresponding pharmacy sales figures during the same period. Defined daily doses (DDDs)
for antibiotics were used as measurement units (WHO ATC/DDD classification). Consumption figures obtained with
the two methods for different registration intervals were compared by use of intraclass correlation analysis and
Bland-Altman statistics.
Results: Broad-spectrum antibiotics accounted for a quarter to one-fifth of all systemic antibiotics (ATC group J01)
used in the hospital and varied between wards, from 12.8 DDDs per 100 bed days in a urological ward to 24.5
DDDs in a pulmonary diseases ward. For the entire study period of 26 weeks, the pharmacy and ward defined
daily doses figures for all broad-spectrum antibiotics differed only by 0.2%; however, for single wards deviations
varied from -4.3% to 6.9%. The intraclass correlation coefficient, pharmacy versus ward data, increased from 0.78 to
0.94 for parenteral broad-spectrum antibiotics with increasing registration periods (1-4 weeks), whereas the
corresponding figures for oral broad-spectrum antibiotics (ciprofloxacin) were from 0.46 to 0.74. For all broad-
spectrum antibiotics and for parenteral antibiotics, limits of agreement between the two methods showed,
according to Bland-Altman statistics, a deviation of ± 5% or less from average mean DDDs at 3- and 4-weeks
registration intervals. Corresponding deviation for oral antibiotics was ± 21% at a 4-weeks interval.
Conclusions: There is a need for caution in interpreting pharmacy sales data aggregated over short registration
intervals, especially so for oral formulations. Even a one-month registration period may be too short.
Background
Antibiotic use in hospitals accounts for 10% or less of
total antibiotic consumption in most countries, but is
characterized by the use of large quantities of broad-
spectrum antibiotics (BSAs). Furthermore, hospital
departments are densely populated with patients who
are at particular risk of acquiring infections of resistant
microorganisms [1,2]. Thus, active surveillance of in-
hospital antibiotic use to prevent inappropriate
prescribing is a fundamental measure in the struggle
against the development of antimicrobial resistance
[3,4].
The most common way of measuring antibiotic use in
hospitals is to apply sales data extracted from hospital
pharmacy computer systems. However, until now in
most European countries pharmacies have not dispensed
antibiotics directly to the patients. A ward-held stock of
antibiotics has been the routine. In a recent survey of
hospital pharmacy practice in Europe it was found that
70% of hospitals hold antibiotic stocks at the wards [5].
When wards purchase drugs from the pharmacy, there
w i l ln e c e s s a r i l yb eat i m el a gf r o mo r d e r i n gu n t i l
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actual drug use might be expected because of variation of
stock size over time, discarding of expired drugs, and
exchanges of drugs between wards.
Moreover, the duration of the registration intervals may
affect the results. In general, short registration intervals
have been advocated, especially when the purpose has
been to evaluate the effects of specific drug interventions
[6-8]. However, the appropriateness of using short regis-
tration intervals has not been assessed. How the duration
of the registration interval impacts the recording of anti-
biotic use has not been scrutinized.
Aim of the study was to explore whether the number of
defined daily doses (DDDs) reported from the pharmacy,
that is to say the sales data to the wards, reflects actual
patient consumption of BSAs. In particular, we wanted to
evaluate the importance of the length of the registration
intervals for the reliability of the pharmacy data.
Methods
Study population
Oslo University Hospital Aker is a 350-bed tertiary hospi-
tal with adult surgical and medical specialities including
regional functions for urology, vascular surgery, and endo-
crinology. In 2007, the number of somatic hospital beds
was 356 and 20 060 patients were admitted for 116 251
days of in-patient treatment. Data on occupied bed-days
were obtained from the hospital administration, where
days of admission and discharge were counted together as
one day.
Five hospital wards were included in the study: a pul-
monary diseases ward, a combined gastrointestinal and
infectious diseases ward, a combined endocrinology and
haematology ward, and two urological wards. These wards
accounted for 28% of all patient treatment in terms of
occupied bed days. The specialties were selected because
of a historically relatively high per-ward total use of BSAs,
which in our hospital are ciprofloxacin (parenteral and
oral) and parenteral formulations of cefuroxime, cefotax-
ime, ceftazidime, ceftriaxone, meropenem, and imipenem/
cilastatin. Ciprofloxacin is the only oral BSA registered in
Norway. Piperacillin+tazobacta mi st h eo n l yr e g i s t e r e d
penicillin with an enzyme inhibitor, but this agent was not
used in our hospital during the study period.
In Norway, a full assortment of antibiotics is normally
stock-piled in the wards and administered by the ward
nurses. Antibiotics are not ordered from the pharmacy on
a per-patient basis. The ward nurses routinely prepare par-
enteral antibiotics, retrieved from the ward stock, just
prior to administration. On rare occasions, when a drug is
out of stock, it will be available from another ward or, in
the daytime, from the hospital pharmacy. An emergency
pharmacy service exists for essential and rarely used drugs;
however, this does not apply for antibacterial agents.
Ward stock accounting
During 26 weeks from October 2006 to April 2007, a
pharmacist performed weekly counts of BSA stock in the
five wards. The number of vials, infusion bags, and tablets
were registered for each ward once a week, before daily
orders of antibiotics were placed to the pharmacy, but
after morning doses of antibiotics were administered to
the patients. The milligram amounts for each antibiotic
were converted to defined daily doses units in accordance
with the latest WHO ATC/DDD version [9].
The weekly amount of antibiotics consumed by patients
(henceforth designated as “ward BSA”) was calculated as
the difference between the previous and the current week
count, and also taking into account input and output to
ward stock. Factors increasing the ward stock size were
delivery from the pharmacy and loan from other wards.
Factors reducing the ward stock size were loan to other
wards, BSAs sent with patients for use after discharge, and
discarding of old drugs. Discarded drugs were registered
electronically in the pharmacy sales system while the other
stock reducing factors were registered manually by ward
nurses.
Because of the lack of a ward stock count during holi-
days in study weeks 10 - 12 and 25 - 26, a weekly average
was used for these weeks. Also, two weeks had to be
omitted from a total of 26 weeks to establish complete 3-
and 4-weeks registration intervals. We chose to omit the
weeks 12 and 26, weeks with incomplete data acquisition,
thus probably reducing the risk of error.
Pharmacy sales data
For each ward, weekly sales figures for BSA DDDs for the
same 26-week period were extracted from the hospital’s
pharmacy computer system (FarmaPro version 4.1.0a,
NAF-data Corp. 2007, Oslo, Norway). In addition to eco-
nomic data, the system registers the number of DDDs for
each antibiotic order placed by the separate wards, as
well as total amounts of antibiotics returned by the same
wards to the pharmacy provided that shelf-life and condi-
tion allow for further use. The resulting sales figures for
different time intervals, designated as “pharmacy BSA”,
were compared with “ward BSA”. We chose to assign a
weekly average for the study weeks 10 - 12 and 25 - 26
also for the pharmacy sales data (see Discussion). The
shortest registration interval was one week, and accumu-
lated periods of two, three, and four weeks were also
investigated.
Statistical analysis
The numbers of DDDs for each BSA and for each ward
obtained by the two methods were entered into a
Microsoft Excel (version 2007) spreadsheet. All entries
and subsequent calculations were double-checked by
two of the investigators (JBH and RM).
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ware version 11 (StataCorpLP, College Station, TX USA).
The reliability or overall agreement of the pharmacy BSA
with ward BSA was assessed by intraclass correlation coef-
ficients (ICC) using a mixed model ANOVA. The theoreti-
cal formula for is ICC=ss
2+se
2, where ss
2 is the between-
subject variance and se
2 is the within-subject variance.
The ICC will be high if the measures are in agreement
(i.e., the slopes of the regression lines are near 1), and the
variation between ward data is large relative to the varia-
tion between pharmacy data measurements. A calculated
ICC = 1 reflects perfect reliability of the method as evalu-
ated against the assumed “gold standard”. An ICC of 0.7 is
commonly used as a threshold of sufficient reliability [10].
Using the method describ e db yB l a n da n dA l t m a n
[11,12], the differences between pairs of DDD measure-
ments for pharmacy BSAs and for ward BSAs were
plotted against their averages. Twelve plots (all antibio-
tics, parenteral antibiotics, and oral antibiotics assessed
for one to four weeks registration intervals) were
inspected for aberrant trends over the measurement
range. Levels of agreement for different combinations
were then determined and related to the average of
mean DDDs for the two measurements.
Results
Use of broad-spectrum antimicrobial agents
BSA use during the 26 study weeks ranged from 12.8
DDDs/100 bed days in one urological ward to 24.5 DDDs/
100 bed days in the pulmonary diseases ward. BSA
amounts ranged from 615.3 DDDs at one urological ward
to 1144.8 DDDs at the pulmonary diseases ward (Table 1),
which represents 19.4% - 26.3% of the total consumption
of all systemic anti-bacterial agents (ATC group J01). In
Table 1 Use of broad-spectrum antibiotics (BSAs)
1 during 26 weeks, pharmacy sales data versus ward stock data.
Wards BSAs PharmacyBSA DDDs
2 WardBSA DDDs Diff. (%)
Pulmonary diseases 1 144.8 1 194.2 -4.3
2
nd generation cephalosporins 445.0 432.5 -2.8
3
rd generation cephalosporins 328.8 360.3 -9.6
Carbapenems 180.0 171.0 5.0
Ciprofloxacin parenteral 16.0 26.4 -65.0
Ciprofloxacin oral 175.0 204.0 -16.6
Gastrointestinal/infectious diseases 877.3 898.1 -2.4
2
nd generation cephalosporins 205.0 231.0 -12.7
3
rd generation cephalosporins 161.3 152.5 5.5
Carbapenems 103.0 96.3 6.5
Ciprofloxacin parenteral 128.0 130.0 -1.6
Ciprofloxacin oral 280.0 288.3 -3.0
Endocrinology/haematology 668.3 676.1 -1.2
2
nd generation cephalosporins 125.0 128.0 -2.4
3
rd generation cephalosporins 101.3 111.3 -9.9
Carbapenems 80.0 76.0 5.0
Ciprofloxacin parenteral 52.0 46.8 10.0
Ciprofloxacin oral 310.0 314.0 -1.3
Urology 1 615.3 572.8 6.9
2
nd generation cephalosporins 70.0 62.5 10.5
3
rd generation cephalosporins 46.3 32.8 29.2
Carbapenems 0 0 -
Ciprofloxacin parenteral 124.0 131.2 -5.8
Ciprofloxacin oral 375.0 346.3 7.7
Urology 2 671.5 628.7 6.4
2
nd generation cephalosporins 72.5 63.0 13.1
3
rd generation cephalosporins 30.0 19.0 36.7
Carbapenems 0 0 -
Ciprofloxacin parenteral 144.0 144.4 -0.3
Ciprofloxacin oral 425.0 402.3 5.3
All specialties 3 977.2 3 969.7 0.2
1BSAs: ciprofloxacin (oral and parenteral), cefuroxime, cefotaxime, ceftazidime, ceftriaxone, meropenem and imipenem/cilastatin
2DDD: defined daily doses
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floxacin was the predominant BSA used. In the pulmonary
diseases ward, cephalosporins accounted for two-thirds of
total BSA use, whereas the use of the various antibiotics
was more evenly distributed in the gastroenterology/infec-
tious diseases ward.
Pharmacy versus ward DDD registrations
During the 26 study weeks there were 1040 dual registra-
tions (pharmacy versus ward data) of the eight BSAs at
the five wards. In 550 of these registrations, no use was
registered by either of the two methods and this was pri-
marily caused by a very low use of carbapenems (e.g. no
use in the urological wards). The number of DDDs that
were discarded (10.5), sent with patients on discharge
(18.0) or loaned to other wards (14.5) represented 1.1% of
the total consumption. Only nine DDDs were borrowed
from other wards.
Total BSA use over 26 weeks measured as ward BSA
was 3 970 DDDs with a weekly range of 104.7 - 257.2
DDDs. The corresponding total number for pharmacy
sales data were almost identical at 3 977 DDDs, with a
weekly range of 41.5 - 324.5 DDDs (Figure 1). The lar-
gest discrepancy between total ward and pharmacy
BSAs was noted in observation weeks 17 - 18 and was
related to oral ciprofloxacin. Half of the total BSA use
in this study was found to be ciprofloxacin and 77% of
this was oral formulation. In both urological wards, the
total pharmacy BSA was markedly higher than ward
BSA (6.4% - 6.9%). This is in contrast to the three medi-
cal wards where the total pharmacy BSA was somewhat
lower than ward BSA (1.2% - 4.3%).
The pharmacy sale to the wards per individual order
of antibiotics varied little for the various parenteral for-
mulations (median 5 - 10 DDDs) as distinct from oral
formulations (ciprofloxacin tablets) for which both lar-
ger bulks and a wider range of order size (5 - 50 DDDs,
median 20) were registered (Figure 2). The total number
of orders varied considerably from 14 (ceftriaxone) to
110 (cefuroxime).
Figure 1 Consumption of broad-spectrum antibiotics in defined daily doses (DDDs) during 26 weeks; pharmacy sales data versus
ward stock measurements (all wards).
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The reliability of pharmacy data as compared to ward
stock accounting increased with longer surveillance
intervals (Table 2). For total BSAs, all wards included,
an intraclass correlation coefficient (ICC) of 0.65 (CI
0.61 - 0.69) was found for one-week intervals whereas
for 4-week registration intervals the ICC was 0.90 (CI
0.88 - 0.93). The reliability of pharmacy data was mark-
edly higher for parenteral than for oral BSAs, the latter
achieving an ICC of 0.74 (CI 0.58 - 0.90) only at four-
Figure 2 Antibiotic orders
1 from wards to the pharmacy for different broad-spectrum antibiotics
2 during 26 weeks (all wards).
1
Median number of defined daily doses per order, interquartile ranges and outliers (circles).
2 Carbapenems include meropenem and imipenem/
cilastatin.
Table 2 Reliability of pharmacy sales compared with ward stock data of broad-spectrum antibiotics (BSAs)
1 for
different registration intervals
Interval No. reg. ICC
2 all BSA (CI
3) ICC parenteral BSA (CI) ICC oral BSA (CI)
1 week 1 040 0.65 (0.61-0.69) 0.78 (0.76 - 0.81) 0.46 (0.32 - 0.59)
2 weeks 520 0.77 (0.74 - 0.81) 0.87 (0.85 - 0.89) 0.53 (0.35-0.70)
3 weeks 360 0.82 (0.79-0.86) 0.93 (0.92 - 0.95) 0.54 (0.32-0.76)
4 weeks 280 0.90 (0.88-0.93) 0.94 (0.92 - 0.95) 0.74 (0.58 - 0.90)
1 Broad-spectrum antibiotics: ciprofloxacin (parenteral and oral), cefuroxime, cefotaxime, ceftazidime, ceftriaxone, meropenem, and imipenem/cilastatin
2 ICC: intraclass correlation coefficient
3 CI: 95% confidence interval
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reached this level at the one-week registration interval.
For all of the 12 combinations of antibiotics (all, par-
enteral, oral) and periods of registrations (one to four
weeks), Bland-Altman statistics revealed mean differ-
ences between -0.136 to 0.158 DDDs. The limits of
agreement for each of the above combinations were
converted to corresponding DDD ranges (Table 3). For
all BSAs and parenteral BSAs, limits of agreement of <
± 5% were found for 3- and 4-weeks registration inter-
vals while oral antibiotics (ciprofloxacin) deviated ± 21%
from the average mean DDD use even at the 4-week
registration interval. Bland-Altman plots (Figure 3)
showed diverging differences with increasing averages of
D D D sf o ro r a lB S A sa n df o rt h es h o r t e rr e g i s t r a t i o n
intervals in general; a trend which was far less pro-
nounced for parenteral BSAs and all BSAs at the 4-
weeks intervals.
Discussion
Accurate information regarding antibiotic consumption
is a prerequisite for evaluating antibiotic use and imple-
menting measures to avoid excessive prescribing and
increased bacterial resistance. To achieve efficient moni-
toring, short registration periods have been advocated,
preferably as short as one month [13]. In this study, we
found that surveillance by use of pharmacy sales data
was sufficiently reliable for the total registration period
of six months. A small mean difference between
measurements for all registration intervals, as demon-
strated by Bland-Altman statistics, implies that our com-
parison of pharmacy with ward registrations was not
burdened with systematic bias. However, when data for
the shorter periods, such as one to four weeks, were
investigated, ICCs indicated that pharmacy sales data
were not sufficiently reliable, particularly so for the one-
to three-week registrations. It will be a clinical decision
to define acceptable limits of agreement. Nonetheless,
t h ew i d eD D Dr a n g ef o ro r a lB S A s( ±2 1 % )e v e na ta
four weeks registration interval seems unacceptable by
any standards.
The amount of BSAs exchanged between wards, dis-
carded due to exceeded durability or given to patients at
discharge was less than 2%, and it was the stock size fluc-
tuations in the wards that accounted for the main discre-
pancy between pharmacy and ward data. The greatest
variations were observed for ciprofloxacin tablets, which
largely explain the less reliable pharmacy figures for oral
compared to parenteral formulations. This in turn is
related to the fact that tablets usually are less voluminous
and also cheaper per DDD and may be stored for longer
periods than injectable preparations.
Few other studies have evaluated the common method
of measuring hospital use of antibiotics by recording
pharmacy dispensing or sales data and, to our knowledge,
none has previously evaluated the impact of the length of
the registration interval. One short report found a poor
correlation between a pharmacy dispensing system and
Table 3 Mean average DDD use
1 of all broad-spectrum antibiotics and corresponding limits of agreement
2 (DDD use
range) for different registration intervals (all wards combined)
Interval Defined daily doses (DDDs)
Antibiotics Mean use Use range (- %; + %) Mean difference
1 week
All 152.8 144.1 - 167.5 (9.6; 9.6) 0.007
Parenteral 92.8 85.0 - 100.6 (8.4; 8.4) -0.003
Oral 60.0 23.9 - 96.2 (60.2; 60.4) 0.079
2 weeks
All 305.6 287.1 - 324.1 (6.1; 6.1) 0.014
Parenteral 185.6 175.5 - 195.7 (5.5; 5.4) -0.006
Oral 120.0 74.9 - 165.4 (37.6; 37.8) 0.158
3 weeks
3
All 466.0 442.8 - 489.2 (5.0; 5.0) 0.031
Parenteral 288.7 274.5 - 294.9 (3.5; 3.6) 0.050
Oral 181.3 120.7 - 241.7 (33.4; 33.3) -0.102
4 weeks
3
All 621.3 600.6 - 642.1 (3.3; 3.3) 0.042
Parenteral 379.6 367.6 - 391.8 (3.2; 3.2) 0.067
Oral 241.7 191.6 - 291.5 (20.7; 20.6) -0.136
1 Sum of averages of paired results (pharmacy sales DDDs and ward stock DDDs)
2 Limits of agreement according to Bland-Altman statistics are expressed as the range of DDDs and percent DDD deviation below and over the mean average
use
3 Weeks 12 and 26 were discarded (see Methods)
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source of data. The investigators speculated that transfer
of antibiotics between wards, wastage, and data-entry
errors may have been the reasons for the discrepancy
[14]. Another study compared pharmacy sales data,
based on pharmacy dispensing, with data from nursing
records and found that up to 20% of parenteral doses of
antibiotics dispensed at the pharmacy were not adminis-
tered to patients [15]. Such a marked deviation is prob-
ably due to delayed transmission of drug information
between the ward and the pharmacy, a situation that
arises when parenteral antibiotics are prepared at the
pharmacy and not near the patient. Neither of the studies
evaluated the length of the registration period.
A limitation of our study is the relatively low BSA
consumption in our institution, such that the number of
registered DDDs was moderate. In hospitals with more
extensive BSA consumption and a larger assortment of
antibiotic substances, the findings may differ. Also of
note, for two periods weekly ward data were missing
because of holidays, and for the weeks in question,
weekly averages were the basis for the analyses. How-
ever, since the corresponding pharmacy sales data were
averaged accordingly, this deviation tend to introduce
bias towards higher levels of agreement (alpha error),
particularly so for the short registration intervals.
We propose that our method of weekly ward stock DDD
accounting is an accurate method for indicating actual
a n t i b i o t i cu s eb yp a t i e n t s .O n l yam u c hm o r el a b o u r -
intensive patient chart review would be more accurate.
Although also our method is demanding and therefore not
practical for routine surveillance, we regard it as well sui-
ted for scientific purposes and for quality assessments of
pharmacy sales figures. In some hospitals, electronic
patient charts have been introduced and this allows for
another method, probably with a high level of accuracy,
for measuring drug consumption [16]. However, for
the immediate future in most European hospitals, the
Figure 3 Accumulated data for antibiotic use at all wards: one-month and four months registration intervals of all BSAs
1 and oral
BSAs (Bland-Altman plots
2 with limits of agreement in gray shade).
1 Broad-spectrum antibiotics.
2 See reference 13.
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lance of use of antibiotics.
Conclusions
Pharmacy sales data for total BSA use were representa-
tive for the actual drug consumption when longer regis-
tration periods were used. For the data to be sufficiently
reliable, a four-week registration period is required for
parenteral formulations, whereas for oral medications
one month is not sufficient. For analyses of BSA sub-
classes and separate hospital units, even these intervals
are probably too short, at least in hospitals with a low-
to-moderate consumption profile.
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